- Home
- BXSL vs LEGN Comparison
BXSL vs LEGN Comparison
Compare BXSL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BXSL | LEGN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BXSL | LEGN |
|---|---|---|
| Price | $23.66 | $18.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $28.13 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 2.6M | 1.7M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.05 | $46.27 |
| Revenue Next Year | N/A | $28.77 |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.30 | $16.24 |
| 52 Week High | $33.73 | $45.30 |
Technical Indicators
Market Signals| Indicator | BXSL | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 49.02 |
| Support Level | $23.30 | $17.46 |
| Resistance Level | $27.04 | $23.68 |
| Average True Range (ATR) | 0.63 | 0.81 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 23.73 | 47.10 |
Price Performance
Historical ComparisonAbout BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.